帕尼培南-倍他米隆治疗血液系统恶性肿瘤感染的初步临床评价

[Preliminary clinical evaluations of panipenem-betamipron in the treatment of hematological malignancy infections].

作者信息

Li Jian-Jun, Jia Yong-Qian, Cui Xu, Huang Jie, He Chuan

机构信息

West China Hospital, Sichuan University, Chengdu, China.

出版信息

Zhonghua Yi Xue Za Zhi. 2012 Feb 21;92(7):452-5. doi: 10.3760/cma.j.issn.00376-2491-2012.07.006.

DOI:10.3760/cma.j.issn.00376-2491-2012.07.006

PMID:22490964

Abstract

OBJECTIVE

To evaluate the clinical efficacy and safety of intravenous panipenem-betamipron in the treatment of hematological malignancies infections.

METHODS

From October 2009 to December 2010, a total of 286 hematological malignancy infection patients were recruited into this open-label, perspective and multicenter clinical trial to receive an intravenous daily dose panipenem-betamipron of 0.5 g every 6 or 8 hours for 7 - 14 days. All clinical change and adverse reactions were recorded.

RESULTS

The total effective rate of panipenem-betamipron in the treatment of hematological malignancy infections was 86.6% (206/238). The effective rates of septicemia, pulmonary infections, urinary tract infections, digestive canal infections, oral infections and other infections were 68.2% (15/22), 89.3% (100/112), 77.8% (14/18), 100% (22/22), 83.3% (10/12) and 86.5% (45/52) respectively. The overall bacterial eradication rate was 85.07% (57/67) and the rate of adverse reactions 5.9% (17/286).

CONCLUSION

Panipenem-betamipron is both safe and effective in the treatment of hematological malignancy infections.

摘要

目的

评价静脉滴注帕尼培南-倍他米隆治疗血液系统恶性肿瘤感染的临床疗效及安全性。

方法

2009年10月至2010年12月，共纳入286例血液系统恶性肿瘤感染患者，进行这项开放标签、前瞻性、多中心临床试验，患者接受静脉滴注帕尼培南-倍他米隆，剂量为0.5 g，每6或8小时1次，疗程7 - 14天。记录所有临床变化及不良反应。

结果

帕尼培南-倍他米隆治疗血液系统恶性肿瘤感染的总有效率为86.6%（206/238）。败血症、肺部感染、泌尿系统感染、消化道感染、口腔感染及其他感染的有效率分别为68.2%（15/22）、89.3%（100/112）、77.8%（14/18）、100%（22/22）、83.3%（10/12）和86.5%（45/52）。细菌总清除率为85.07%（57/67），不良反应发生率为5.9%（17/286）。